Source: Equipment Home, reprinting is not allowed without authorization, and it can only be reproduced 24 hours later.
It is reported that yesterday, the groundbreaking ceremony of the global headquarters and innovation and industrialization base project of Shanghai Micro-Invasive Xinmai Medical Technology (Group) Co., Ltd. (688016.SH, hereinafter referred to as " Xinmai Medical ™") was successfully held in the Shanghai International Medical Park of Zhangjiang Science City, Pudong.
Xinmai Medical™ Chairman Mr. Bloomberg, Xinmai Medical™ President Dr. Zhu Qing, the president of Xinmai Medical™, finished the highlight of lion dance
Minimally Invasive® Group Chief Marketing Officer and Chairman of Greater China Executive Committee, Xinmai Medical™ Chairman Mr. Bloomberg , Xinmai Medical™ President Dr. Zhu Qing , and the company's managers and employee representatives attended the groundbreaking ceremony. witnessed this important moment of .
01
Global Headquarters and Innovation and
Industrial Base Project
Xinmai Medical™ Global Headquarters and Innovation and Industrial Base Project is located in the Shanghai International Medical Park 34B-01 plot, with a total construction area of 140,000 square meters . The project is based on the industrial development requirements of Shanghai Zhangjiang High-Tech International Medical Park, and relies on the innovative advantages accumulated by Xinmai Medical™ over the years, and strives to build an important source of scientific and technological innovation and a benchmark base for modern manufacturing innovation.
Xinmai Medical Global Headquarters and Innovation and Industrialization Base Project The total investment is about 1.1 billion , facing Qingdai Road in the north, Landi Road in the south, Tianxiong Road in the west, and Banxia Road in the east. The project base consists of three plots, from to west, developed and constructed by Xinmai (34-04 plot), Shentong (34-03 plot), Xintong (34-02 plot), and other three companies, respectively, with a total construction area of about 150,000 square meters.
Xinmai Medical™ Global Headquarters and Innovation and Industrialization Base Project renderings
Xinmai Medical™ President Dr. Zhu Qing expressed his gratitude to the government departments, all sectors of society for their strong support and efforts of the project team in his speech at the ceremony. He said: "Today's groundbreaking ceremony of is another important milestone on the road to innovative development of Xinmai Medical™. Since its establishment, Xinmai Medical™ has driven the company's rapid development with continuous innovation and has become a leading enterprise in the field of aortic and peripheral vascular interventional medical devices in China.
In 2019, the company's first batch of login science and technology innovation board was listed, entering the fast lane of development, and is accelerating the development strategy of group and globalization. The construction of the global headquarters and innovation and industrialization base project of Xinmai Medical™, It will help the company further optimize its product strategic layout, improve its industrial scale, strengthen its comprehensive competitive strength, and lay the foundation for achieving long-term high-quality growth of its company's performance."
It is reported that after the project is completed, it will become a characteristic industrial park that integrates R&D, testing, production, office, and service , and meets the business development needs of future large-scale production.
02
Little Giant Enterprise
Xinmai Medical
Shanghai Minimally Invasive Xinmai Medical Technology (Group) Co., Ltd. (hereinafter referred to as "Xinmai Medical™") is a subsidiary of Minimally Invasive Medical Science Co., Ltd. (Minily Invasive® Group, 00853.HK). was registered and established in Shanghai International Medical Park in 2012.
was listed on the Science and Technology Innovation Board in 2019 (688016.SH) . It is a Shanghai high-tech enterprise, Shanghai science and technology giant enterprise, the first batch of specialized and new "little giant" enterprise , Shanghai Enterprise Technology Center, Multinational Company R&D Center, and AAAA credit enterprise .
Xinmai Medical™ products have entered more than 1,400 hospitals nationwide, saving the lives of more than 120,000 patients. 's domestic market share of aortic products has reached 28%, ranking first in domestic brands for many years, and its international business covers 19 countries and regions in Europe, Latin America, Southeast Asia and other places.
Xinmai Medical™ focuses on the research, development, production, sales and services of aortic and peripheral vascular interventional medical devices. has three subsidiaries: Lanmai Medical™ (mainly peripheral venous business), Hongmai Medical™ (mainly peripheral artery business) and Tuomai Medical™ (mainly tumor interventional business).
The company currently has 13 products on the market, mainly including thoracic and abdominal aortic coating stents, intraoperative stents, drug balloon dilated catheters, peripheral vascular stents, balloon dilated catheters and other products . Among them, 5 products have been CE certified . Six of the products that have been on the market and under development have been approved to enter the "National Special Review Procedure for Innovative Medical Devices", and are in the leading position in the industry.
The company's operation headquarters is located in Shanghai and currently has more than 800 employees. The company adheres to the concept of ", a brand of patients, ". Xinmai Medical™ has always been committed to "providing accessibility, truth, goodness, beauty and comprehensive medical solutions for the treatment of blood circulation diseases". is committed to building a world-leading leading emerging high-tech medical group with people-oriented through technological innovation.
03
Close price Increase deviation value cumulatively exceeds 30%
As a leading enterprise in the field of aortic and peripheral vascular interventional treatment, Xinmai Medical empowers stable growth in performance through differentiated product pipelines. It is reported that Xinmai Medical's stock has risen by more than 30% on the 3rd. As of yesterday, Xinmai Medical issued an announcement on abnormal fluctuations in stock trading.
The company's stock price decline value for the daily closing price in three consecutive trading days on October 13, October 14 and October 17 has exceeded 30%. According to relevant regulations, it is an abnormal fluctuation in stock trading.
After the company's self-inspection and verification with the controlling shareholder, there is no major information that should be disclosed but has not been disclosed. As of yesterday, the company's closing price was 211.22 yuan per share. According to the company's latest rolling market released by CSI Index Co., Ltd. , the company's latest rolling market earnings ratio is 37.90 times , and the company's special equipment manufacturing industry in the past month is 30.75 times. company's price-to-earnings ratio is higher than industry price-to-earnings ratio level .
As of the closing data this afternoon, each share is 226.10 yuan , opening today is 210.99 yuan, the highest is 228.88 yuan, and the lowest is 206.52 yuan. Its increase increased by 7.04% , with a transaction amount of 1.09 billion yuan and a total market value of 16.274 billion yuan.
In the first half of 2022, the company achieved operating income of 459 million yuan, and increased by 26.64% year-on-year; net profit attributable to shareholders was 215 million yuan, an increase of 16.42% year-on-year. showed strong operating strength against the backdrop of repeated domestic epidemics. 's company's R&D investment totaled 60 million yuan, an increase of 20.92% year-on-year. accounts for 13.06% of its operating income, further increasing R&D investment in the field of peripheral artery and venous vascular intervention.
04
Rich product line
It is reported that the company insists on the research and development and innovation of independent intellectual property products, and gradually realizes the role transformation from technology to technology-led leadership. After years of deep cultivation and continuous R&D investment, the Heart Mai Medical has formed a product line including the thoracic aortic stent system, the abdominal aortic stent system, the peripheral arterial intervention products, and the balloon dilated catheter. has 13 products obtained medical device product registration certificates, 5 products obtained CE certificates, and 6 products have entered the national special approval procedures for innovative medical devices.
It is worth mentioning that recently, Lanmai Medical, a subsidiary of Xinmai Medical, independently developed the first Fishhawk® mechanical thrombectomy catheter. has been officially approved to enter the special review procedure for innovative medical devices of the National Drug Administration (NMPA). This is the 7th independently developed by Xinmai Medical and the 2nd product of Bluemai Medical™ that has entered the "green channel" for the national innovative medical device review.
At present, the company has conducted prospective and multicenter clinical research on evaluating the safety and effectiveness of Fishhawk® mechanical thrombectomy catheter in the treatment of acute iliac deep venous thrombosis, and the relevant research is progressing smoothly. During the clinical trial, the excellent thrombectomy catheter of Fishhawk® mechanical thrombectomy has been fully recognized by clinical experts.
In April this year, the Fontus® branched intraoperative stent system (hereinafter referred to as "Fontus® branched intraoperative stent") independently developed by the Zhongshan Hospital affiliated to Fudan University was successfully implanted after its first clinical case after its launch.
Fontus® branched intraoperative stent is a new generation of intraoperative stent independently developed by Xinmai Medical™. It was approved to enter the National Special Review Procedure for Innovative Medical Devices in 2018. It was approved for sale in December 2021. It is the first branched surgical special stent in China and even the world.
Its collateral structure can facilitate stent implantation into the left subclavian artery, reduce the difficulty of surgery, and significantly shorten the time of left vertebrae ischemia and cerebral perfusion. is conducive to reducing the related risks caused by deep free and anastomosis of the left subclavian artery, and reduce nervous system complications such as recurrent laryngeal nerve. 's unique design concept and excellent clinical performance have also been fully recognized by the clinician teams of various centers in their application.
—
believes that the construction of Xinmai Medical's global headquarters and innovation and industrialization base project will lay a solid foundation for the company to take off higher and farther, and be fully prepared. In the future, will Xinmai Medical become a world-leading high-tech medical group and bring new innovations to the field of blood circulation diseases? The subsequent Device Home will continue to be updated.
